BridgeBio Pharma Inc (NASDAQ: BBIO) open the trading on Thursday, with great promise as it jumped 0.11% to $62.73, before settling in for the price of $62.66 at the close. Taking a more long-term approach, BBIO posted a 52-week range of $21.72-$69.48.
It was noted that the giant of the Healthcare sector posted annual sales growth of -3.04% over the last 5 years. Meanwhile, its Annual Earning per share during the time was -3.04%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -21.21%. This publicly-traded company’s shares outstanding now amounts to $192.63 million, simultaneously with a float of $163.63 million. The organization now has a market capitalization sitting at $12.09 billion. At the time of writing, stock’s 50-day Moving Average stood at $54.94, while the 200-day Moving Average is $42.69.
BridgeBio Pharma Inc (BBIO) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. BridgeBio Pharma Inc’s current insider ownership accounts for 15.09%, in contrast to 88.48% institutional ownership. Preceding that transaction, on Oct 29 ’25, Company’s Director sold 198,359 for 66.58, making the whole transaction’s value amount to 13,206,528. This particular insider is now the holder of 679,979 in total.
BridgeBio Pharma Inc (BBIO) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.58 per share during the current fiscal year. BridgeBio Pharma Inc’s EPS decrease for this current 12-month fiscal period is -21.21% and is forecasted to reach -1.67 in the upcoming year.
BridgeBio Pharma Inc (NASDAQ: BBIO) Trading Performance Indicators
Let’s observe the current performance indicators for BridgeBio Pharma Inc (BBIO). It’s Quick Ratio in the last reported quarter now stands at 3.76. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 34.17.
In the same vein, BBIO’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -4.19, a figure that is expected to reach -0.73 in the next quarter, and analysts are predicting that it will be -1.67 at the market close of one year from today.
Technical Analysis of BridgeBio Pharma Inc (BBIO)
[BridgeBio Pharma Inc, BBIO] recent stats showed that its last 5-days Average volume was poorer than the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 51.27% While, its Average True Range was 62.64.
Raw Stochastic average of BridgeBio Pharma Inc (BBIO) in the period of the previous 100 days is set at 77.37%, which indicates a major rise in contrast to 59.65% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 3.09 that was higher than 1.90 volatility it exhibited in the past 100-days period.
